News 13.05.2025 CUTISS has completed patient recruitment in its Phase 2 clinical trial evaluating the safety and efficacy of denovoSkin™ in children with severe burns. This randomized, controlled trial compares denovoSkin™ to the current standard of care, autografting, using an intra-patient control design. It is one of three Phase 2 trials designed to...
News 13.05.2025 Schlieren (Zürich), Switzerland, May 13, 2025 – Kuros Biosciences (“Kuros” or the “Company”) a leader in innovative biologic technologies, is pleased to announce today’s Capital Markets Day on Tuesday, May 13, 2025, at 9am CEST, at the Hyatt Regency Zürich Airport, The Circle, Zürich, Switzerland. The event will also be...
News 08.05.2025 Lightium won the Prix Strategis 2025. The startup develops photonic chips for telecommunications and artificial intelligence. The Strategis Prize is awarded by HEC Espace Entreprise in Lausanne. Lightium, a start-up that specializes in photonic integrated circuits, won the Prix Strategis for the 32nd time this year. Based in the Bio-Technopark Schlieren-Zurich,...
News 07.05.2025 CUTISS has been granted a new patent in the United States for a core element of its automated platform used to manufacture personalized, bio-engineered human skin grafts. The patent (US Patent No. 12,286,611), titled “Tissue culture vessel for preparation of compressed hydrogel skin grafts and related methods and systems,” protects a...
News 27.04.2025 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 25, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced the...